Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A

Leonard A. Valentino, Michael Recht, J. Dipaola, A. D. Shapiro, S. W. Pipe, N. Ewing, J. Urgo, T. Bullock, M. Simmons, C. Deguzman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third-generation recombinant FVIII product that is free of animal and human protein additives, tolerance was achieved in nine (75%), including seven of 10 patients (70%) with high-titre inhibitors. ITI is ongoing in two patients and not yet successful; immune tolerance failed in the third patient. The median time to success was 4.0 months for group as a whole and for patients with high-titre inhibitors. Treatment was well tolerated, and no adverse events were observed. Advate was found to be equivalent to other FVIII products with regard to both ITI success rates and the incidence of adverse effects when used in these immune tolerance regimens.

Original languageEnglish (US)
Pages (from-to)718-726
Number of pages9
JournalHaemophilia
Volume15
Issue number3
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Immune Tolerance
Factor VIII
Hemophilia A
Incidence
Proteins

Keywords

  • Advate
  • Haemophilia A
  • Immune tolerance induction
  • Inhibitor
  • Third-generation recombinant factor VIII

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. / Valentino, Leonard A.; Recht, Michael; Dipaola, J.; Shapiro, A. D.; Pipe, S. W.; Ewing, N.; Urgo, J.; Bullock, T.; Simmons, M.; Deguzman, C.

In: Haemophilia, Vol. 15, No. 3, 2009, p. 718-726.

Research output: Contribution to journalArticle

Valentino, LA, Recht, M, Dipaola, J, Shapiro, AD, Pipe, SW, Ewing, N, Urgo, J, Bullock, T, Simmons, M & Deguzman, C 2009, 'Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A', Haemophilia, vol. 15, no. 3, pp. 718-726. https://doi.org/10.1111/j.1365-2516.2008.01960.x
Valentino, Leonard A. ; Recht, Michael ; Dipaola, J. ; Shapiro, A. D. ; Pipe, S. W. ; Ewing, N. ; Urgo, J. ; Bullock, T. ; Simmons, M. ; Deguzman, C. / Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A. In: Haemophilia. 2009 ; Vol. 15, No. 3. pp. 718-726.
@article{cee3d90de3444198a28303a9f8d4b402,
title = "Experience with a third generation recombinant factor VIII concentrate (Advate{\circledR}) for immune tolerance induction in patients with haemophilia A",
abstract = "The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third-generation recombinant FVIII product that is free of animal and human protein additives, tolerance was achieved in nine (75{\%}), including seven of 10 patients (70{\%}) with high-titre inhibitors. ITI is ongoing in two patients and not yet successful; immune tolerance failed in the third patient. The median time to success was 4.0 months for group as a whole and for patients with high-titre inhibitors. Treatment was well tolerated, and no adverse events were observed. Advate was found to be equivalent to other FVIII products with regard to both ITI success rates and the incidence of adverse effects when used in these immune tolerance regimens.",
keywords = "Advate, Haemophilia A, Immune tolerance induction, Inhibitor, Third-generation recombinant factor VIII",
author = "Valentino, {Leonard A.} and Michael Recht and J. Dipaola and Shapiro, {A. D.} and Pipe, {S. W.} and N. Ewing and J. Urgo and T. Bullock and M. Simmons and C. Deguzman",
year = "2009",
doi = "10.1111/j.1365-2516.2008.01960.x",
language = "English (US)",
volume = "15",
pages = "718--726",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A

AU - Valentino, Leonard A.

AU - Recht, Michael

AU - Dipaola, J.

AU - Shapiro, A. D.

AU - Pipe, S. W.

AU - Ewing, N.

AU - Urgo, J.

AU - Bullock, T.

AU - Simmons, M.

AU - Deguzman, C.

PY - 2009

Y1 - 2009

N2 - The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third-generation recombinant FVIII product that is free of animal and human protein additives, tolerance was achieved in nine (75%), including seven of 10 patients (70%) with high-titre inhibitors. ITI is ongoing in two patients and not yet successful; immune tolerance failed in the third patient. The median time to success was 4.0 months for group as a whole and for patients with high-titre inhibitors. Treatment was well tolerated, and no adverse events were observed. Advate was found to be equivalent to other FVIII products with regard to both ITI success rates and the incidence of adverse effects when used in these immune tolerance regimens.

AB - The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third-generation recombinant FVIII product that is free of animal and human protein additives, tolerance was achieved in nine (75%), including seven of 10 patients (70%) with high-titre inhibitors. ITI is ongoing in two patients and not yet successful; immune tolerance failed in the third patient. The median time to success was 4.0 months for group as a whole and for patients with high-titre inhibitors. Treatment was well tolerated, and no adverse events were observed. Advate was found to be equivalent to other FVIII products with regard to both ITI success rates and the incidence of adverse effects when used in these immune tolerance regimens.

KW - Advate

KW - Haemophilia A

KW - Immune tolerance induction

KW - Inhibitor

KW - Third-generation recombinant factor VIII

UR - http://www.scopus.com/inward/record.url?scp=65449143524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449143524&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2008.01960.x

DO - 10.1111/j.1365-2516.2008.01960.x

M3 - Article

C2 - 19298383

AN - SCOPUS:65449143524

VL - 15

SP - 718

EP - 726

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 3

ER -